RESEARCH TRIANGLE PARK, NC--(Marketwire - September 11, 2008) - According to a new study by
Cutting Edge Information, tyrosine kinase inhibitors may have five oncology
drugs with annual sales over $1 billion by 2013.
This list of blockbuster oncology drugs includes Novartis' Gleevec. Annual
sales of Gleevec are projected to steadily grow to $4.6 billion dollars in
2012, making it a top five oncology drug. There are four other approved
tyrosine kinase inhibitors that are estimated to surpass $1 billion in
annual sales by 2013, one of which is Pfizer's Sutent, which treats renal
cell carcinoma.
The new report, "Oncology Market Forecast to 2013," is a comprehensive
study of more than 135 oncology drugs. The study includes detailed
forecasts for each drug and forecasts for individual drug classes and top
oncology drug manufacturers. To learn more, download our free brochure at
http://www.cuttingedgeinfo.com/oncology/TA220_Download.asp
"Tyrosine kinase inhibitors have proven themselves as effective treatments
for many types of cancer," said Eric Bolesh, research manager at Cutting
Edge Information. "That is one of the reasons pharma companies continue to
invest heavily in new drugs within this class of oncology treatments. We
will see many more treatments coming out of this class over the next few
years."
The pipeline of upcoming tyrosine kinase inhibitors is quite robust. Major
drug companies like Pfizer, Wyeth,
Sanofi-Aventis, GlaxoSmithKline, AstraZeneca and Amgen all have drugs from
this class in Phase III development. It is this promising pipeline,
combined with the commercial success that has characterized existing drugs
in this class, that lead analysts to estimate a $17 billion market for
tyrosine kinase inhibitors by 2013. In terms of sales within the oncology
space, tyrosine kinase inhibitors are second only to monoclonal antibodies.
The 420+ page study examines 17 monoclonal antibodies and more than 120
other drugs, and provides the following market analysis:
-- Individual Drug Profiles -- Drug profiles include information about
drugs' competitive, strategic and market growth positions.
-- Oncology Indication Market Outlook -- Detailed outlooks for the
breast, colorectal, lung and prostate cancer and leukemia markets.
-- Company Profiles -- Oncology breakdowns for companies that either have
established oncology franchises or exciting development pipelines for new
cancer compounds.
Contact Information: CONTACT INFORMATION:
Eric Bolesh
919-433-0209